These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 16431394)

  • 21. The effect of tryptophan depletion on the action of haloperidol in MK-801-treated rats.
    Bubeníková V; Horácek J; Kozený J; Platilová V; Závesická L; Pálenícek T; Höschl C
    Eur J Pharmacol; 2004 Oct; 502(1-2):109-16. PubMed ID: 15464096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective effect of adenosine reuptake inhibitors in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Pharmacology; 2007; 79(3):171-83. PubMed ID: 17377417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter.
    Fachinetto R; Villarinho JG; Wagner C; Pereira RP; Avila DS; Burger ME; Calixto JB; Rocha JB; Ferreira J
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1478-86. PubMed ID: 17669571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
    Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
    Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1130-8. PubMed ID: 17513028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of daily chlorpromazine administration on behavioural and physiological parameters in the rat.
    Nsimba SE
    Indian J Physiol Pharmacol; 2009; 53(3):209-18. PubMed ID: 20329367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quetiapine reverses altered locomotor activity and tyrosine hydroxylase immunoreactivity in rat caudate putamen following long-term haloperidol treatment.
    Zhang Y; Xu H; He J; Yan B; Jiang W; Li X; Li XM
    Neurosci Lett; 2007 Jun; 420(1):66-71. PubMed ID: 17466452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serotonin(1A) receptor agonism in the expression of behavioral dopaminergic supersensitivity in subchronic haloperidol treated rats.
    Batool F; Haleem DJ
    Pak J Pharm Sci; 2008 Oct; 21(4):411-20. PubMed ID: 18930864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The characteristics of the development of cataleptic phenomena during the action of a new Ukrainian neuroleptic--a butyrophenone derivative--in experiments on mice].
    Shapovalova VO; Mykhaĭlov VS; Shapovalov VV
    Fiziol Zh (1994); 1999; 45(3):114-7. PubMed ID: 10439301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haloperidol (but not ziprasidone) withdrawal potentiates sensitization to the hyperlocomotor effect of cocaine in mice.
    Fukushiro DF; Carvalho Rde C; Ricardo VP; Alvarez Jdo N; Ribeiro LT; Frussa-Filho R
    Brain Res Bull; 2008 Sep; 77(2-3):124-8. PubMed ID: 18721669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of haloperidol and clozapine on some behavioral effects in rats.
    Nowakowska E; Kus K; Krzyzanski W; Czubak A
    Arzneimittelforschung; 2006; 56(12):807-13. PubMed ID: 17260667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats.
    Haleem DJ; Samad N; Haleem MA
    Pharmacol Biochem Behav; 2007 May; 87(1):115-21. PubMed ID: 17498786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppressive effect of clozapine but not haloperidol on the increases of neuropeptide-degrading enzymes and glial cells in MK-801-treated rat brain regions.
    Arif M; Chikuma T; Ahmed MM; Yoshida S; Kato T
    Neurosci Res; 2007 Feb; 57(2):248-58. PubMed ID: 17141345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute and chronic administration of clozapine produces greater proconvulsant actions than haloperidol on focal hippocampal seizures in freely moving rats.
    Minabe Y; Watanabe K; Nishimura T; Ashby CR
    Synapse; 1998 Jul; 29(3):272-8. PubMed ID: 9635898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Afobazole decreases motor side effects induced by haloperidol].
    Seredenin SB; Garibova TA; Kuznetsova AL; Voronin MV; Iarkova MA; Voronina TA
    Eksp Klin Farmakol; 2009; 72(1):15-8. PubMed ID: 19334504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Some behavioural effects of carbamazepine - comparison with haloperidol.
    Nowakowska E; Kus K; Czubak A; Glowacka D; Matschay A
    J Physiol Pharmacol; 2007 Jun; 58(2):253-64. PubMed ID: 17622695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
    Bardin L; Auclair A; Kleven MS; Prinssen EP; Koek W; Newman-Tancredi A; Depoortère R
    Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antipsychotics produce locomotor impairment in larval zebrafish.
    Giacomini NJ; Rose B; Kobayashi K; Guo S
    Neurotoxicol Teratol; 2006; 28(2):245-50. PubMed ID: 16527449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates.
    Casey DE; Bruhwyler J; Delarge J; Géczy J; Liégeois JF
    Psychopharmacology (Berl); 2001 Sep; 157(3):228-35. PubMed ID: 11605077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia.
    Haleem DJ
    J Coll Physicians Surg Pak; 2006 Aug; 16(8):556-62. PubMed ID: 16899192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.